Ondexxya (andexanet alfa): Avoid use of andexanet prior to heparinization
About
This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.
Documents
Key facts
| Medicine name |
Ondexxya
|
| Active substance |
andexanet alfa
|
| Therapeutic area (MeSH) |
Drug-Related Side Effects and Adverse Reactions
|
| Procedure number |
EMEA/H/C/004108/II/0011
|
| Regulatory outcome |
Variation
|
| DHPC type |
Adverse event
|
| Human ATC code |
V03AB
|
| Dissemination date |
04/11/2020
|